Intensive treat-to-target statin therapy in high-risk Japanese patients with hypercholesterolemia and diabetic retinopathy: Report of a randomized study

Diabetes Care

Volumn 41, Issue 6, 2018, Pages 1275-1284

  Itoh, Hiroshi ^a   Komuro, Issei ^b   Takeuchi, Masahiro ^c   Akasaka, Takashi ^d   Daida, Hiroyuki ^e   Egashira, Yoshiki ^f   Fujita, Hideo ^g   Higaki, Jitsuo ^h   Hirata, Ken Ichi ⁱ   Ishibashi, Shun ^g   Isshiki, Takaaki ^j   Ito, Sadayoshi ^k   Kashiwagi, Atsunori ^l   Kato, Satoshi ^b   Kitagawa, Kazuo ^m   Kitakaze, Masafumi ⁿ   Kitazono, Takanari ^o   Kurabayashi, Masahiko ^p   Miyauchi, Katsumi ^e   Murakami, Tomoaki ^q   Murohara, Toyoaki ^r   Node, Koichi ^s   Ogawa, Susumu ^t   Saito, Yoshihiko ^u   Seino, Yoshihiko ^v   Shigeeda, Takashi ^w   Shindo, Shunya ^x   Sugawara, Masahiro ^y   Sugiyama, Seigo ^z   Terauchi, Yasuo ^aa   Tsutsui, Hiroyuki ^ab   Ueshima, Kenji ^ac   Utsunomiya, Kazunori ^ad   Yamagishi, Masakazu ^ae   Yamazaki, Tsutomu ^af   Yo, Shoei ^ag   Yokote, Koutaro ^ah   Yoshida, Kiyoshi ^ai   Yoshimura, Michihiro ^ad   Yoshimura, Nagahisa ^aj   Nakao, Kazuwa ^q   Nagai, Ryozo ^g   more..

^a KEIO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d WAKAYAMA MEDICAL UNIVERSITY   (Japan)

^e JUNTENDO UNIVERSITY   (Japan)

^f Sakura Hospital   (Japan)

^g JICHI MEDICAL UNIVERSITY   (Japan)

^h EHIME UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

ⁱ KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j Ageo Central General Hospital   (Japan)

^k TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l Kusatsu General Hospital   (Japan)

^m TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

ⁿ NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^o KYUSHU UNIVERSITY   (Japan)

^p GUNMA UNIVERSITY   (Japan)

^q KYOTO UNIVERSITY   (Japan)

^r NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^s SAGA UNIVERSITY   (Japan)

^t TOHOKU UNIVERSITY HOSPITAL   (Japan)

^u NARA MEDICAL UNIVERSITY   (Japan)

^v NIPPON MEDICAL SCHOOL CHIBA HOKUSOH HOSPITAL   (Japan)

^w Ideta Eye Hospital   (Japan)

^x TOKYO MEDICAL UNIVERSITY   (Japan)

^y Sugawara Clinic   (Japan)

^z Jinnouchi Hospital   (Japan)

^aa YOKOHAMA CITY UNIVERSITY   (Japan)

^ab KYUSHU UNIVERSITY   (Japan)

^ac KYOTO UNIVERSITY HOSPITAL   (Japan)

^ad JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^ae KANAZAWA UNIVERSITY   (Japan)

^af UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^ag Yo Clinic   (Japan)

^ah CHIBA UNIVERSITY   (Japan)

^ai THE SAKAKIBARA HEART INSTITUTE OF OKAYAMA   (Japan)

^aj Kitano Hospital   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; C REACTIVE PROTEIN; CREATINE KINASE; CREATININE; FLUINDOSTATIN; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; BLOOD PRESSURE MEASUREMENT; BRAIN DISEASE; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY FAILURE; CONFERENCE PAPER; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIABETIC RETINOPATHY; DRUG SAFETY; FEMALE; FOLLOW UP; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HEPATOBILIARY DISEASE; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; INTENSIVE CARE; JAPAN; JAPANESE (PEOPLE); KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MULTICENTER STUDY; MYOPATHY; OPEN STUDY; PRIMARY PREVENTION; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RHABDOMYOLYSIS; TRIACYLGLYCEROL BLOOD LEVEL; URINARY TRACT DISEASE; AGED; BLOOD; CLINICAL TRIAL; COMORBIDITY; COMPLICATION; MIDDLE AGED;

AGED; CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; COMORBIDITY; DIABETIC RETINOPATHY; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INCIDENCE; JAPAN; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 85047460883     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-2224     Document Type: Conference Paper

References (26)

1. Turner RC, Millns H, Neil HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ 1998;316:823-828
2. Sone H, Tanaka S, Tanaka S, et al.; Japan Diabetes Complications Study Group. Serumlevel of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes: Subanalysis of the Japan Diabetes Complications Study (JDCS). J Clin Endocrinol Metab 2011;96:3448-3456
3. Gaede P, Pedersen O. Intensive integrated therapy of type 2 diabetes: Implications for long-term prognosis. Diabetes 2004;53(Suppl. 3):S39-S47
4. Kearney PM, Blackwell L, Collins R, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy of cholesterol-lowering therapy in 18, 686 people with diabetes in 14 randomised trials of statins: Ameta-analysis. Lancet 2008;371:117-125
5. Kramer CK, Rodrigues TC, Canani LH, Gross JL, Azevedo MJ. Diabetic retinopathy predicts allcause mortality and cardiovascular events in both type 1 and 2 diabetes: Meta-analysis of observational studies. Diabetes Care 2011;34: 1238-1244
6. Ohno T, Kinoshita O, Fujita H, et al. Detecting occult coronary artery disease followed by early coronary artery bypass surgery in patients with diabetic retinopathy: Report from a diabetic retinocoronary clinic. J Thorac Cardiovasc Surg 2010; 139:92-97
7. Baigent C, Blackwell L, Emberson J, et al.; Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from170, 000 participants in 26 randomised trials. Lancet 2010;376:1670-1681
8. Stone NJ, Robinson JG, Lichtenstein AH, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of theAmerican College of Cardiology/American Heart Association Task Force on Practice Guidelines. [published correction appears in J Am Coll Cardiol 2014;63:3024-3025, 2015;66:2812].
9. Stone NJ, Robinson JG, Lichtenstein AH, et al.; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of theAmerican College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014;63 (25 Pt. B):2889-2934
10. Ueshima K, Itoh H, Kanazawa N, et al.; EMPATHY study group. Rationale and design of the standard versus intEnsive statin therapy for hypercholesteroleMic Patients with DiAbetic RetinopaTHY (EMPATHY) study: A randomized controlled trial. J Atheroscler Thromb 2016;23: 976-990
11. Brunzell JD, Davidson M, Furberg CD, et al.; American Diabetes Association; American College of Cardiology Foundation. Lipoprotein management in patients with cardiometabolic risk: Consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008;31:811-822
12. Teramoto T, Sasaki J, Ueshima H, et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular diseases for Japanese. J Atheroscler Thromb 2007;14:45-50
13. Sandhu S, Wiebe N, Fried LF, Tonelli M. Statins for improving renal outcomes: A metaanalysis. J Am Soc Nephrol 2006;17:2006-2016
14. Colhoun HM, Betteridge DJ, Durrington PN, et al.; CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696
15. Sever PS, Poulter NR, Dahlöf B, et al. Reduction in cardiovascular events with atorvastatin in 2, 532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005;28:1151-1157
16. Collins R, Armitage J, Parish S, Sleigh P, Peto R; Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterollowering with simvastatin in 5963 people with diabetes: A randomised placebo-controlled trial. Lancet 2003;361:2005-2016
17. Ogawa H, Nakayama M, Morimoto T, et al.; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Investigators. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: A randomized controlled trial. JAMA 2008;300:2134-2141
18. Cannon CP, Blazing MA, Giugliano RP, et al.; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-2397
19. Baigent C, Keech A, Kearney PM, et al.; Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278
20. Sabatine MS, Giugliano RP, Keech AC, et al.; FOURIER Steering Committee and Investigators. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376:1713-1722
21. Bowman L, Hopewell JC, Chen F, et al.; HPS3/ TIMI55-REVEAL Collaborative Group. Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med 2017;377:1217-1227
22. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al.; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-559
23. Hosomi N, Nagai Y, Kohriyama T, et al.; J-STARS Collaborators. The Japan Statin Treatment Against Recurrent Stroke (J-STARS): A multicenter, randomized, open-label, parallel-group study. EBio-Medicine 2015;2:1071-1078
24. Goldstein LB, Amarenco P, Szarek M, et al.; SPARCL Investigators. Hemorrhagic stroke in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study. Neurology 2008;70:2364-2370
25. Rajpathak SN, Kumbhani DJ, Crandall J, Barzilai N, AldermanM, Ridker PM. Statin therapy and risk of developing type 2 diabetes: A metaanalysis. Diabetes Care 2009;32:1924-1929
26. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: A collaborative metaanalysis of randomised statin trials. Lancet 2010; 375:735-742